These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19930189)

  • 1. Design and analysis of crossover trials for absorbing binary endpoints.
    Nason M; Follmann D
    Biometrics; 2010 Sep; 66(3):958-65. PubMed ID: 19930189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical approaches for design and analysis of clinical trials of infertility treatments: crossover designs and the Mantel-Haenszel method are recommended.
    Takada M; Sozu T; Sato T
    Pharm Stat; 2015; 14(3):198-204. PubMed ID: 25776032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and analysis issues for crossover designs in phase I clinical studies.
    Boon PC; Roes KC
    J Biopharm Stat; 1999 Mar; 9(1):109-28. PubMed ID: 10091913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal crossover designs for logistic regression models in pharmacodynamics.
    Waterhouse TH; Eccleston JA; Duffull SB
    J Biopharm Stat; 2006; 16(6):881-94. PubMed ID: 17146986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crossover designs in lower extremity wounds.
    Reed JF
    Int J Low Extrem Wounds; 2003 Sep; 2(3):158-63. PubMed ID: 15866840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combined score test for binary and ordinal endpoints from clinical trials.
    Whitehead J; Branson M; Todd S
    Stat Med; 2010 Feb; 29(5):521-32. PubMed ID: 20082364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The place of the crossover design in infertility trials: a maximum likelihood approach.
    McDonnell J; Goverde AJ; Vermeiden JP
    Hum Reprod; 2004 Nov; 19(11):2537-44. PubMed ID: 15459169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis strategies for adaptive designs with multiple endpoints.
    Chang M; Chow SC
    J Biopharm Stat; 2007; 17(6):1189-200. PubMed ID: 18027225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
    Slob W; Moerbeek M; Rauniomaa E; Piersma AH
    Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On design considerations and randomization-based inference for community intervention trials.
    Gail MH; Mark SD; Carroll RJ; Green SB; Pee D
    Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Odds ratio for 2 × 2 tables: Mantel-Haenszel estimator, profile likelihood, and presence of surrogate responses.
    Banerjee B; Biswas A
    J Biopharm Stat; 2014; 24(3):649-59. PubMed ID: 24697719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of randomized discontinuation design.
    Freidlin B; Simon R
    J Clin Oncol; 2005 Aug; 23(22):5094-8. PubMed ID: 15983399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Planning and analysis of cross-over trials in infertility.
    Makubate B; Senn S
    Stat Med; 2010 Dec; 29(30):3203-10. PubMed ID: 21170914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling and design of cross-over trials.
    Jones B; Donev AN
    Stat Med; 1996 Jul; 15(13):1435-46. PubMed ID: 8841653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the role of Baseline measurements for crossover designs under the self and mixed carryover effects model.
    Liang Y; Carriere KC
    Biometrics; 2010 Mar; 66(1):140-8. PubMed ID: 19432775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of vaccine equivalence/non-inferiority trials with correlated multiple binomial endpoints.
    Kong L; Kohberger RC; Koch GG
    J Biopharm Stat; 2006; 16(4):555-72. PubMed ID: 16892913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.